Literature DB >> 29229837

Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.

Songwang Hou1, Heike Fölsch2, Ke Ke1, Joan Cook Mills3, Rosalind Ramsey-Goldman4, Ming Zhao5.   

Abstract

Phosphatidylethanolamine (PE) is a major phospholipid species with important roles in membrane trafficking and reorganization. Accumulating clinical data indicate that the presence of circulating antibodies against PE is positively correlated with the symptoms of antiphospholipid syndromes (APS), including thrombosis and repeated pregnancy loss. However, PE is generally sequestered inside a normal resting cell, and the mechanism by which circulating anti-PE antibodies access cellular PE remains unknown. The studies presented here were conducted with synthetic PE-binding agents, plasma samples from patients with anti-PE autoimmunity, and purified anti-PE antibodies. The results suggest that the cellular vulnerability to anti-PE antibodies may be mediated by the binding of PE molecules in the membrane of the early endosome. Endosomal PE binding led to functional changes in endothelial cells, including declines in proliferation and increases in the production of reactive oxygen species, as well as the expression of inflammatory molecules. Collectively, our findings provide insight into the etiology of anti-PE autoimmunity and, because endosomes are of central importance in almost all types of cells, could have important implications for a wide range of biological processes.

Entities:  

Keywords:  antiphosphatidylethanolamine; antiphospholipid syndromes; duramycin; early endosome; phosphatidylethanolamine

Mesh:

Substances:

Year:  2017        PMID: 29229837      PMCID: PMC5748199          DOI: 10.1073/pnas.1714027115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  Phospholipid-assisted refolding of an integral membrane protein. Minimum structural features for phosphatidylethanolamine to act as a molecular chaperone.

Authors:  M Bogdanov; M Umeda; W Dowhan
Journal:  J Biol Chem       Date:  1999-04-30       Impact factor: 5.157

2.  Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses.

Authors:  T Sugi; J Katsunuma; S Izumi; J A McIntyre; T Makino
Journal:  Fertil Steril       Date:  1999-06       Impact factor: 7.329

3.  Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus.

Authors:  E Balada; J Ordi-Ros; F Paredes; J Villarreal; M Mauri; M Vilardell-Tarrés
Journal:  Scand J Rheumatol       Date:  2001       Impact factor: 3.641

4.  Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies.

Authors:  D R Wagenknecht; D R Fastenau; R J Torry; D G Becker; W M LeFor; C B Carter; B W Haag; J A McIntyre
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

Review 5.  Anti-phosphatidylethanolamine (aPE) antibodies: a survey.

Authors:  J A Mcintyre; D R Wagenknecht
Journal:  J Autoimmun       Date:  2000-09       Impact factor: 7.094

6.  NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation.

Authors:  F Nomura; T Kawai; K Nakanishi; S Akira
Journal:  Genes Cells       Date:  2000-03       Impact factor: 1.891

7.  Phospholipids as determinants of membrane protein topology. Phosphatidylethanolamine is required for the proper topological organization of the gamma-aminobutyric acid permease (GabP) of Escherichia coli.

Authors:  Wei Zhang; Heidi A Campbell; Steven C King; William Dowhan
Journal:  J Biol Chem       Date:  2005-05-12       Impact factor: 5.157

8.  Essential roles of receptor-interacting protein and TRAF2 in oxidative stress-induced cell death.

Authors:  Han-Ming Shen; Yong Lin; Swati Choksi; Jamie Tran; Tian Jin; Lufen Chang; Michael Karin; Jianke Zhang; Zheng-gang Liu
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  Antiphospholipid antibodies and renal transplantation: a risk assessment.

Authors:  J A McIntyre; D R Wagenknecht
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis.

Authors:  M Karmochkine; P Cacoub; J C Piette; P Godeau; M C Boffa
Journal:  Clin Exp Rheumatol       Date:  1992 Nov-Dec       Impact factor: 4.473

View more
  2 in total

1.  Is Oxidative Stress an Emerging Player in the Thrombosis of Patients with Anti-Phosphatidylethanolamine Autoantibodies?

Authors:  Xavier Heim; Daniel Bertin; Noémie Resseguier; Abdelouahab Beziane; Audrey Metral; Alexandre Brodovitch; Régis Guieu; Jean-Guillaume Steinberg; Marcel Blot-Chabaud; Pierre-Emmanuel Morange; Jean-Louis Mege; Nathalie Bardin
Journal:  J Clin Med       Date:  2022-02-27       Impact factor: 4.241

2.  Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps.

Authors:  Jacob G Eide; Jeffanie Wu; Whitney W Stevens; Junqin Bai; Songwang Hou; Julia H Huang; Jacob Rosenberg; Paul Utz; Stephanie Shintani-Smith; David B Conley; Kevin C Welch; Robert C Kern; Kathryn E Hulse; Anju T Peters; Leslie C Grammer; Ming Zhao; Paul Lindholm; Robert P Schleimer; Bruce K Tan
Journal:  Clin Exp Allergy       Date:  2022-03-14       Impact factor: 5.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.